Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B-cell non-Hodgkin lymphoma in LMIC setting.

Venkatraman RadhakrishnanVenkatakrishnan KritthivasanBalaji Thiruvengadam KothandanPrasanth SrinivasanGargi Das Jaikumar Govindaswamy Ramamoorthy

Published in: Pediatric blood & cancer (2023)

Our study demonstrates a significant improvement in outcomes in pediatric B-NHL compared to previous reports from LMICs, achieved through a 25% reduction in chemotherapy dose intensity and the addition of rituximab.

Keyphrases

diffuse large b cell lymphoma
locally advanced
high intensity
chronic lymphocytic leukemia
squamous cell carcinoma
radiation therapy
adverse drug
adipose tissue
rectal cancer
metabolic syndrome
skeletal muscle
free survival
insulin resistance
childhood cancer